Free Trial

Issuance-Related Selling

US TSYS

Unlikely the trigger, but certainly adding to this morning's sell-off: rate lock sales hedging surge in incoming high-grade corporate debt issuance:

  • Date $MM Issuer (Priced *, Launch #)
  • 03/21 $Benchmark GlaxoSmithKline (GSK) 7Pt: 2NC1 +110a, 2NC1 SOFR, 3Y +110a, 5Y +130a, 7Y +140a, 10Y +160a, 30Y +190a
  • 03/21 $Benchmark Humana 7Y +165a
  • 03/21 $Benchmark Sempra 3Y +130a, 7Y +170a
  • 03/21 $Benchmark ING 4NC3 +175a, 4NC3 SOFR, 6NC5 +190a, 11NC10 +220a
  • 03/21 $Benchmark Philippines Bank 5Y +125a, 10.5Y +165a, 25Y 4.7%a
  • 03/21 $Benchmark KEB Hana Bank 3Y, 5Y investor calls

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.